DOCSLIB.ORG

1 Means Downregulated in Tumor 1 Means Upregulated in Tumor

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
1 Means Downregulated in Tumor 1 Means Upregulated in Tumor Supplementary Table1A Qmin was the smallest Q in the six comprisons null indicates that the Q>=0.1 -1 means downregulated in tumor 1 means upregulated in tumor Normal vs IA Normal vs IB Normal vs IIA Normal vs IIB Normal vs IIIA Normal vs IIIB RefsequenTotal RanQmin regulatioRank Qvalue regulatioRank Qvalue regulatioQvalue regulatioQvalue regulatioRank Qvalue regulatioRank Qvalue Symbol NM_002576 6 1.96E-06 1 0 4.60E-06 1 0 1.96E-06 null null null null 1 3 5.85E-06 1 3 0.094625 PAK1 NM_014448 9 3.26E-06 1 5 6.09E-06 1 0 3.26E-06 null null 1 6.14E-06 1 0 6.25E-06 null 4 null ARHGEF16 NM_001136 10 4.26E-06 -1 3 4.26E-06 -1 3 4.38E-06 null null -1 5.80E-06 -1 2 5.27E-06 -1 2 0.010202 AGER NM_005308 10 5.48E-06 -1 3 5.48E-06 -1 3 5.94E-06 -1 7.48E-05 -1 8.23E-06 -1 2 7.57E-06 -1 2 0.013074 GRK5 NM_000442 11 1.66E-06 -1 3 2.61E-06 -1 3 1.66E-06 -1 0.067008 -1 2.02E-06 -1 3 3.42E-06 -1 2 0.010327 PECAM1 NM_001752 11 1.69E-06 -1 3 2.66E-06 -1 3 1.69E-06 -1 3.17E-05 -1 2.06E-06 -1 4 3.52E-06 -1 1 0.017122 CAT NM_004684 11 1.7E-06 -1 3 2.68E-06 -1 3 1.70E-06 null null -1 2.09E-06 -1 3 3.55E-06 -1 2 0.009204 SPARCL1 NM_003734 11 1.89E-06 -1 3 2.93E-06 -1 3 1.89E-06 -1 0.077317 -1 2.34E-06 -1 3 3.96E-06 -1 2 0.010948 AOC3 NM_000552 11 1.92E-06 -1 3 2.98E-06 -1 3 1.92E-06 -1 0.078834 -1 2.37E-06 -1 3 4.04E-06 -1 2 0.010422 VWF NM_005574 11 1.99E-06 -1 3 3.17E-06 -1 3 1.99E-06 -1 0.08477 -1 2.46E-06 -1 3 4.18E-06 -1 2 0.016332 LMO2 NM_001449 11 2.31E-06 -1 3 3.69E-06 -1 3 2.31E-06 -1 0.085543 -1 2.84E-06 -1 3 4.87E-06 -1 2 0.012035 FHL1 NM_006829 11 2.33E-06 -1 3 3.71E-06 -1 3 2.33E-06 -1 0.097837 null null -1 3 4.93E-06 -1 2 0.011249 C10orf116 NM_000873 11 2.46E-06 -1 3 3.98E-06 -1 3 2.46E-06 null null -1 3.00E-06 -1 3 5.21E-06 -1 2 0.021281 ICAM2 NM_000304 11 2.46E-06 -1 3 4.00E-06 -1 3 2.46E-06 null null -1 3.02E-06 -1 3 5.24E-06 -1 2 0.010202 PMP22 NM_003278 11 2.82E-06 -1 3 4.79E-06 -1 3 2.82E-06 -1 4.84E-05 -1 3.46E-06 -1 3 6.19E-06 -1 2 0.000118 CLEC3B NM_000668 11 2.84E-06 -1 3 4.81E-06 -1 3 2.84E-06 null null -1 3.49E-06 -1 3 6.24E-06 -1 2 0.009252 ADH1B NM_001025 11 3.24E-06 -1 3 5.6E-06 -1 3 3.24E-06 null null -1 3.86E-06 -1 3 7.16E-06 -1 2 0.009761 CD34 NM_001424 11 4.84E-06 -1 3 4.84E-06 -1 3 5.25E-06 -1 0.08597 -1 6.69E-06 -1 3 6.11E-06 -1 2 0.007996 EMP2 NM_001386 11 4.99E-06 -1 3 4.99E-06 -1 3 5.37E-06 -1 0.087117 -1 6.92E-06 -1 3 6.40E-06 -1 2 0.009628 DPYSL2 NM_001753 11 5.25E-06 -1 3 5.25E-06 -1 3 5.61E-06 -1 6.86E-05 -1 7.77E-06 -1 2 7.08E-06 -1 3 0.07378 CAV1 NM_003773 12 1.76E-06 -1 3 2.78E-06 -1 3 1.76E-06 -1 0.071795 -1 2.17E-06 -1 3 3.71E-06 -1 3 0.051036 HYAL2 NM_002404 12 1.96E-06 -1 3 3.09E-06 -1 4 1.96E-06 -1 0.095483 -1 2.41E-06 -1 3 4.14E-06 -1 2 0.010401 MFAP4 NM_005964 12 2.03E-06 -1 3 3.20E-06 -1 3 2.03E-06 null null null null -1 3 4.22E-06 -1 3 0.022456 MYH10 NM_001146 12 2.1E-06 -1 3 3.31E-06 -1 5 2.1E-06 -1 3.43E-05 -1 2.56E-06 -1 3 4.36E-06 -1 1 0.014558 ANGPT1 NM_004840 12 2.12E-06 -1 3 3.35E-06 -1 3 2.12E-06 null null -1 2.59E-06 -1 3 4.43E-06 -1 3 0.022038 ARHGEF6 NM_000115 12 2.16E-06 -1 3 3.40E-06 -1 3 2.16E-06 -1 0.086154 -1 2.65E-06 -1 3 4.50E-06 -1 3 0.012389 EDNRB NM_004166 12 2.49E-06 -1 3 4.06E-06 -1 3 2.49E-06 null null null null -1 3 5.35E-06 -1 3 0.024999 CCL14 NM_000820 12 2.56E-06 -1 3 4.18E-06 -1 3 2.56E-06 -1 0.091375 null null -1 3 5.52E-06 -1 3 0.030775 GAS6 NM_005795 12 2.61E-06 -1 3 4.22E-06 -1 4 2.61E-06 null null -1 3.14E-06 -1 3 5.64E-06 -1 2 0.010088 CALCRL NM_023037 12 2.73E-06 -1 3 4.47E-06 -1 3 2.73E-06 null null -1 3.32E-06 -1 3 5.97E-06 -1 3 0.021313 FRY NM_000049 12 2.87E-06 -1 3 2.87E-06 -1 3 2.88E-06 null null -1 4.12E-06 -1 3 3.79E-06 -1 3 0.054458 ASPA NM_002084 12 2.95E-06 -1 3 2.95E-06 -1 3 2.99E-06 -1 0.092781 -1 4.24E-06 -1 3 3.93E-06 -1 3 0.014216 GPX3 NM_005512 12 3.09E-06 -1 3 5.35E-06 -1 3 3.09E-06 null null -1 3.76E-06 -1 3 6.75E-06 -1 3 0.030853 LRRC32 NM_000698 12 3.51E-06 -1 3 3.51E-06 -1 3 3.68E-06 null null -1 5.08E-06 -1 3 4.60E-06 -1 3 0.077521 ALOX5 NM_000216 12 3.84E-06 -1 3 3.84E-06 -1 3 3.96E-06 -1 0.095726 -1 5.42E-06 -1 4 4.85E-06 -1 2 0.010696 KAL1 NM_001860 12 4.8E-06 -1 3 4.80E-06 -1 3 5.20E-06 null null -1 6.64E-06 -1 3 6.04E-06 -1 3 0.094571 SLC31A2 NM_014767 12 5.2E-06 -1 3 5.20E-06 -1 3 5.54E-06 -1 0.09727 -1 7.35E-06 -1 3 6.81E-06 -1 3 0.014281 SPOCK2 NM_004484 12 7.34E-06 -1 3 7.34E-06 -1 3 8.75E-06 -1 0.000103 -1 1.19E-05 -1 3 9.60E-06 -1 3 0.012077 GPC3 NM_001442 12 1.78E-05 -1 3 1.78E-05 -1 3 1.85E-05 -1 0.098319 -1 2.84E-05 -1 3 2.07E-05 -1 3 0.009489 FABP4 NM_001795 12 2.5E-05 -1 3 2.5E-05 -1 3 2.77E-05 -1 0.000412 -1 4.57E-05 -1 3 2.83E-05 -1 3 0.010015 CDH5 NM_000517 12 3.84E-05 -1 3 3.84E-05 -1 3 4.14E-05 null null -1 5.88E-05 -1 3 4.48E-05 -1 3 0.030495 HBA2 NM_001024 12 4.16E-05 -1 3 4.16E-05 -1 3 4.48E-05 null null -1 6.33E-05 -1 3 4.89E-05 -1 3 0.009963 TGFBR2 NM_001460 13 1.8E-06 -1 3 2.81E-06 -1 3 1.80E-06 null null -1 2.21E-06 -1 4 4.41E-06 -1 3 0.021362 FMO2 NM_001343 13 1.94E-06 -1 3 3.05E-06 -1 3 1.94E-06 null null null null -1 3 4.10E-06 null 4 null DAB2 NM_001233 13 2.39E-06 -1 3 3.85E-06 -1 3 2.39E-06 -1 0.089345 -1 2.93E-06 -1 3 5.05E-06 null 4 null CAV2 NM_003380 13 2.87E-06 -1 3 4.96E-06 -1 3 2.87E-06 null null -1 3.55E-06 -1 3 6.33E-06 null 4 null VIM NM_000118 13 2.89E-06 -1 3 5.02E-06 -1 3 2.89E-06 -1 0.090011 -1 3.58E-06 -1 4 6.38E-06 -1 3 0.036157 ENG NM_001089 13 2.97E-06 -1 3 5.18E-06 -1 3 2.97E-06 null null -1 3.64E-06 -1 4 2.99E-05 -1 3 0.010336 ABCA3 NM_000361 13 3.12E-06 -1 3 5.42E-06 -1 4 3.12E-06 -1 0.094222 -1 3.79E-06 -1 3 6.80E-06 -1 3 0.038974 THBD NM_000062 13 4.62E-06 -1 3 4.62E-06 -1 3 4.89E-06 null null -1 6.14E-06 -1 4 5.85E-06 -1 3 0.050187 SERPING1 NM_000459 13 9.42E-06 -1 3 9.42E-06 -1 3 1.08E-05 -1 0.000165 -1 1.47E-05 -1 4 3.05E-05 -1 3 0.018369 TEK NM_005277 14 2.07E-06 -1 3 3.27E-06 -1 3 2.07E-06 -1 0.085804 -1 2.53E-06 -1 5 4.29E-06 -1 3 0.01324 GPM6A NM_004106 14 2.22E-06 -1 3 3.56E-06 -1 3 2.22E-06 null null null null -1 4 4.7E-06 null 4 null FCER1G NM_005641 14 2.29E-06 1 7 8.05E-06 1 0 2.29E-06 null null null null 1 3 2.77E-05 null 4 null TAF6 NM_003713 14 2.88E-06 -1 3 4.99E-06 -1 3 2.88E-06 null null -1 3.56E-06 -1 6 2.44E-05 -1 2 0.01268 PPAP2B NM_001067 14 3.24E-06 1 4 5.11E-05 1 0 3.24E-06 null null null null 1 7 5.98E-05 1 3 0.083378 TOP2A NM_001444 14 3.26E-06 -1 3 3.26E-06 -1 3 3.36E-06 -1 0.083766 -1 4.7E-06 -1 4 4.23E-06 null 4 null FABP5 NM_000784 14 6.84E-06 -1 3 6.84E-06 -1 3 7.92E-06 null null -1 1.06E-05 -1 4 8.96E-06 null 4 null CYP27A1 NM_003638 14 7.03E-06 -1 5 7.03E-06 -1 3 8.18E-06 null null -1 1.11E-05 -1 3 9.27E-06 -1 3 0.061157 ITGA8 NM_001001 14 1.35E-05 -1 3 1.35E-05 -1 3 1.43E-05 null null -1 1.96E-05 -1 5 1.49E-05 -1 3 0.017771 GPM6B NM_002017 15 1.68E-06 -1 3 2.66E-06 -1 3 1.68E-06 null null -1 2.05E-06 -1 5 3.50E-06 null 4 null FLI1 NM_003128 15 1.8E-06 -1 7 2.82E-06 -1 3 1.80E-06 -1 0.082613 -1 2.21E-06 -1 3 3.81E-06 -1 2 0.011043 SPTBN1 NM_001033 15 1.81E-06 -1 3 2.83E-06 -1 6 1.81E-06 -1 0.0731 -1 2.22E-06 -1 3 3.83E-06 -1 3 0.009777 ADARB1 NM_001870 15 1.82E-06 -1 5 3.44E-06 -1 3 1.82E-06 null null -1 2.23E-06 -1 4 4.52E-06 -1 3 0.049748 CPA3 NM_021953 15 1.92E-06 1 8 5.54E-06 1 0 1.92E-06 null null null null 1 3 5.60E-06 null 4 null FOXM1 NM_014880 15 2.82E-06 -1 3 2.84E-06 -1 5 2.82E-06 null null -1 4.04E-06 -1 4 3.71E-06 -1 3 0.030639 CD302 NM_002060 15 2.91E-06 -1 7 5.08E-06 -1 3 2.91E-06 null null -1 3.59E-06 -1 3 6.43E-06 -1 2 0.00972 GJA4 NM_003070 15 3.18E-06 -1 5 4.27E-06 -1 3 3.18E-06 null null -1 4.47E-06 -1 5 4.07E-06 -1 2 0.000269 SMARCA2 NM_004515 15 3.24E-06 1 0 6.01E-06 1 6 3.24E-06 1 0.000274 1 6.10E-06 1 5 1.87E-05 null 4 null ILF2 NM_006097 15 3.31E-06 -1 5 0.000166 -1 3 3.31E-06 null null -1 3.92E-06 -1 4 0.000269 -1 3 0.052605 MYL9 NM_002543 15 3.75E-06 -1 3 3.75E-06 -1 3 3.93E-06 null null -1 5.38E-06 -1 6 0.003464 -1 3 0.067067 OLR1 NM_001854 15 3.76E-06 1 0 5.09E-06 1 8 3.76E-06 null null 1 5.35E-06 1 5 1.58E-05 1 2 8.96E-05 COL11A1 NM_006307 15 4.09E-06 -1 3 4.09E-06 -1 3 4.23E-06 null null -1 5.52E-06 -1 5 1.04E-05 null 4 null SRPX NM_000313 15 4.46E-06 -1 3 4.46E-06 -1 3 4.62E-06 null null -1 6.01E-06 -1 6 0.015235 -1 3 0.049767 PROS1 NM_000491 15 6.4E-06 -1 3 6.40E-06 -1 5 7.56E-06 null null -1 9.8E-06 -1 3 8.40E-06 null 4 null C1QB NM_005037 15 1.39E-05 -1 3 1.39E-05 -1 3 1.51E-05 null null -1 2.17E-05 -1 5 2.08E-05 null 4 null PPARG NM_000587 15 3.56E-05 -1 3 3.56E-05 -1 6 3.84E-05 null null -1 5.49E-05 -1 3 3.84E-05 -1 3 0.026391 C7 NM_021102 16 1.85E-06 1 7 1.13E-05 1 0 1.85E-06 null null 1 2.75E-06 1 5 1.43E-05 null 4 null SPINT2 NM_000527 16 1.88E-06 -1 3 2.90E-06 -1 5 1.88E-06 -1 0.088354 -1 2.33E-06 -1 5 5.67E-06 -1 3 0.054867 LDLR NM_002444 16 1.93E-06 -1 3 2.99E-06 -1 3 1.93E-06 null null -1 2.38E-06 -1 6 0.013883 null 4 null MSN NM_007161 16 2.44E-06 -1 5 7.68E-06 -1 3 2.44E-06 null null -1 2.99E-06 -1 4 1.22E-05 null 4 null LST1 NM_001801 16 2.53E-06 -1 3 4.14E-06 -1 7 2.53E-06 null null -1 3.06E-06 -1 3 5.42E-06 -1 3 0.010292 CDO1 NM_000507 16 2.54E-06 -1 5 8.75E-06 -1 3 2.54E-06 null null -1 3.07E-06 -1 4 5.45E-06 null 4 null FBP1 NM_003277 16 3.26E-06 -1 7 6.80E-06 -1 3 3.26E-06 null null -1 4.57E-06 -1 4 8.76E-06 -1 2 0.000165 CLDN5 NM_001885 16 3.34E-06 -1 7 4.44E-06 -1 3 3.34E-06 null null -1 4.68E-06 -1 3 4.20E-06 -1 3 0.035961 CRYAB NM_000906 16 3.38E-06 -1 7 7.04E-06 -1 3 3.38E-06 -1 5.49E-05 -1 4.76E-06 -1 3 4.30E-06 -1 3 0.009492 NPR1 NM_001629 16 4.19E-06 -1 5 4.19E-06 -1 3 4.30E-06 null null -1 5.68E-06 -1 5 6.40E-06 -1 3 0.085119 ALOX5AP NM_021136 16 6.24E-06 -1 5 1.35E-05 -1 3 6.24E-06
Load more

Recommended publications
  • Screening and Identification of Key Biomarkers in Clear Cell Renal Cell Carcinoma Based on Bioinformatics Analysis
    bioRxiv preprint doi: https://doi.org/10.1101/2020.12.21.423889; this version posted December 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Screening and identification of key biomarkers in clear cell renal cell carcinoma based on bioinformatics analysis Basavaraj Vastrad1, Chanabasayya Vastrad*2 , Iranna Kotturshetti 1. Department of Biochemistry, Basaveshwar College of Pharmacy, Gadag, Karnataka 582103, India. 2. Biostatistics and Bioinformatics, Chanabasava Nilaya, Bharthinagar, Dharwad 580001, Karanataka, India. 3. Department of Ayurveda, Rajiv Gandhi Education Society`s Ayurvedic Medical College, Ron, Karnataka 562209, India. * Chanabasayya Vastrad [email protected] Ph: +919480073398 Chanabasava Nilaya, Bharthinagar, Dharwad 580001 , Karanataka, India bioRxiv preprint doi: https://doi.org/10.1101/2020.12.21.423889; this version posted December 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract Clear cell renal cell carcinoma (ccRCC) is one of the most common types of malignancy of the urinary system. The pathogenesis and effective diagnosis of ccRCC have become popular topics for research in the previous decade. In the current study, an integrated bioinformatics analysis was performed to identify core genes associated in ccRCC. An expression dataset (GSE105261) was downloaded from the Gene Expression Omnibus database, and included 26 ccRCC and 9 normal kideny samples. Assessment of the microarray dataset led to the recognition of differentially expressed genes (DEGs), which was subsequently used for pathway and gene ontology (GO) enrichment analysis.
    [Show full text]
  • Dissert 1 Title
    GENETIC AND BIOCHEMICAL ANALYSIS OF ESSENTIAL ENZYMES IN TRIACYLGLYCEROL SYNTHESIS IN ARABIDOPSIS By KIMBERLY LYNN COTTON A dissertation submitted in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY WASHINGTON STATE UNIVERSITY Molecular Plant Sciences DECEMBER 2015 © Copyright by KIMBERLY LYNN COTTON, 2015 All Rights Reserved To the Faculty of Washington State University: The members of the Committee appointed to examine the dissertation of KIMBERLY LYNN COTTON find it satisfactory and recommend that it be accepted. ____________________________________________ John A. Browse, Ph.D., Chair _____________________________________________ Michael M. Neff, Ph.D. _____________________________________________ Thomas W. Okita, Ph.D. _____________________________________________ John J. Wyrick, Ph.D. ii ACKNOWLEDGMENTS To my PI John Browse, thank you for your support, guidance and patience over the years. To my committee, John Browse, Michael Neff, Thomas Okita, and John Wyrick, thank you for your insightful discussions and suggestions. To my collaborators Jay Shockey, Anushobha Regmi, Neil Adhikari, John Browse, and Phil Bates, thanks for the great work and great times. To Browse Lab members past and present, thanks for the help, guidance and wonderful memories. To the undergraduate students who have helped me over the years, thank you for all your help in making this project possible; and with a special thank you to Arlene, Tesa, Breana, and “no-longer-undergrads” David and Barbara Cotton for their particular dedication to this project. And finally, a huge thank you to my family and friends who have loved and supported me throughout this venture. Go Cougs! iii GENETIC AND BIOCHEMICAL ANALYSIS OF ESSENTIAL ENZYMES IN TRIACYLGLYCEROL SYNTHESIS IN ARABIDOPSIS Abstract by Kimberly Lynn Cotton, Ph.D.
    [Show full text]
  • Propranolol-Mediated Attenuation of MMP-9 Excretion in Infants with Hemangiomas
    Supplementary Online Content Thaivalappil S, Bauman N, Saieg A, Movius E, Brown KJ, Preciado D. Propranolol-mediated attenuation of MMP-9 excretion in infants with hemangiomas. JAMA Otolaryngol Head Neck Surg. doi:10.1001/jamaoto.2013.4773 eTable. List of All of the Proteins Identified by Proteomics This supplementary material has been provided by the authors to give readers additional information about their work. © 2013 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 10/01/2021 eTable. List of All of the Proteins Identified by Proteomics Protein Name Prop 12 mo/4 Pred 12 mo/4 Δ Prop to Pred mo mo Myeloperoxidase OS=Homo sapiens GN=MPO 26.00 143.00 ‐117.00 Lactotransferrin OS=Homo sapiens GN=LTF 114.00 205.50 ‐91.50 Matrix metalloproteinase‐9 OS=Homo sapiens GN=MMP9 5.00 36.00 ‐31.00 Neutrophil elastase OS=Homo sapiens GN=ELANE 24.00 48.00 ‐24.00 Bleomycin hydrolase OS=Homo sapiens GN=BLMH 3.00 25.00 ‐22.00 CAP7_HUMAN Azurocidin OS=Homo sapiens GN=AZU1 PE=1 SV=3 4.00 26.00 ‐22.00 S10A8_HUMAN Protein S100‐A8 OS=Homo sapiens GN=S100A8 PE=1 14.67 30.50 ‐15.83 SV=1 IL1F9_HUMAN Interleukin‐1 family member 9 OS=Homo sapiens 1.00 15.00 ‐14.00 GN=IL1F9 PE=1 SV=1 MUC5B_HUMAN Mucin‐5B OS=Homo sapiens GN=MUC5B PE=1 SV=3 2.00 14.00 ‐12.00 MUC4_HUMAN Mucin‐4 OS=Homo sapiens GN=MUC4 PE=1 SV=3 1.00 12.00 ‐11.00 HRG_HUMAN Histidine‐rich glycoprotein OS=Homo sapiens GN=HRG 1.00 12.00 ‐11.00 PE=1 SV=1 TKT_HUMAN Transketolase OS=Homo sapiens GN=TKT PE=1 SV=3 17.00 28.00 ‐11.00 CATG_HUMAN Cathepsin G OS=Homo
    [Show full text]
  • Construction of Prognostic Microrna Signature for Human Invasive Breast Cancer by Integrated Analysis
    Journal name: OncoTargets and Therapy Article Designation: Original Research Year: 2019 Volume: 12 OncoTargets and Therapy Dovepress Running head verso: Shi et al Running head recto: Shi et al open access to scientific and medical research DOI: 189265 Open Access Full Text Article ORIGINAL RESEARCH Construction of prognostic microRNA signature for human invasive breast cancer by integrated analysis This article was published in the following Dove Medical Press journal: OncoTargets and Therapy Wei Shi* Background: Despite the advances in early detection and treatment methods, breast cancer Fang Dong* still has a high mortality rate, even in those patients predicted to have a good prognosis. The Yujia Jiang purpose of this study is to identify a microRNA signature that could better predict prognosis in Linlin Lu breast cancer and add new insights to the current classification criteria. Changwen Wang Materials and methods: We downloaded microRNA sequencing data along with correspond- Jie Tan ing clinicopathological data from The Cancer Genome Atlas (TCGA). Of 1,098 breast cancer patients identified, 253 patients with fully characterized microRNA profiles were selected for Wen Yang analysis. A three-microRNA signature was generated in the training set. Subsequently, the per- Hui Guo formance of the signature was confirmed in a validation set. After construction of the signature, Jie Ming* we conducted additional experiments, including flow cytometry and the Cell Counting Kit-8 Tao Huang* assay, to illustrate the correlation of this microRNA signature with breast cancer cell cycle, Department of Breast and Thyroid apoptosis, and proliferation. Surgery, Union Hospital, Tongji Results: Three microRNAs (hsa-mir-31, hsa-mir-16-2, and hsa-mir-484) were identified to Medical College, Huazhong University of Science and Technology, Wuhan be significantly and independently correlated with patient prognosis, and performed with good 430022, China stability.
    [Show full text]
  • Anti-Inflammatory Role of Curcumin in LPS Treated A549 Cells at Global Proteome Level and on Mycobacterial Infection
    Anti-inflammatory Role of Curcumin in LPS Treated A549 cells at Global Proteome level and on Mycobacterial infection. Suchita Singh1,+, Rakesh Arya2,3,+, Rhishikesh R Bargaje1, Mrinal Kumar Das2,4, Subia Akram2, Hossain Md. Faruquee2,5, Rajendra Kumar Behera3, Ranjan Kumar Nanda2,*, Anurag Agrawal1 1Center of Excellence for Translational Research in Asthma and Lung Disease, CSIR- Institute of Genomics and Integrative Biology, New Delhi, 110025, India. 2Translational Health Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, 110067, India. 3School of Life Sciences, Sambalpur University, Jyoti Vihar, Sambalpur, Orissa, 768019, India. 4Department of Respiratory Sciences, #211, Maurice Shock Building, University of Leicester, LE1 9HN 5Department of Biotechnology and Genetic Engineering, Islamic University, Kushtia- 7003, Bangladesh. +Contributed equally for this work. S-1 70 G1 S 60 G2/M 50 40 30 % of cells 20 10 0 CURI LPSI LPSCUR Figure S1: Effect of curcumin and/or LPS treatment on A549 cell viability A549 cells were treated with curcumin (10 µM) and/or LPS or 1 µg/ml for the indicated times and after fixation were stained with propidium iodide and Annexin V-FITC. The DNA contents were determined by flow cytometry to calculate percentage of cells present in each phase of the cell cycle (G1, S and G2/M) using Flowing analysis software. S-2 Figure S2: Total proteins identified in all the three experiments and their distribution betwee curcumin and/or LPS treated conditions. The proteins showing differential expressions (log2 fold change≥2) in these experiments were presented in the venn diagram and certain number of proteins are common in all three experiments.
    [Show full text]
  • Supplementary Table 5. Functional Annotation of the Largest Gene Cluster(221 Element)
    Annotation Tool AFFYID VALUE SYMBOL LOCUSLINK OMIM GENENAME GENEONTOLOGY SUMMARY [Proteome FUNCTION:] Expressed 203054_s_at TCTA 6988 600690 T-cell leukemia translocation altered gene tumor suppressor ubiquitously [Proteome FUNCTION:] May be involved in protein-protein interactions; contains five WD 44563_at FLJ10385 55135 hypothetical protein FLJ10385 domains (WD-40 repeats) [Proteome FUNCTION:] Weakly similarity to 212261_at TNRC15 26058 trinucleotide repeat containing 15 a region of rat nestin (Rn.9701) [SUMMARY:] Actin alpha 1 which is expressed in skeletal muscle is one of six different actin isoforms which have been identified. Actins are highly conserved proteins that are involved in cell motility, actin filament; motor activity; muscle structure and integrity. Alpha actins are a contraction; muscle development; structural major constituent of the contractile 203872_at ACTA1 58 102610 actin, alpha 1, skeletal muscle constituent of cytoskeleton apparatus. [SUMMARY:] Annexin VIII belong to the family of Ca (2+) dependent phospholipid binding proteins (annexins), and has a high 56% identity to annexin V (vascular anticoagulant-alpha). It was initially isolated as 2.2 kb vascular anticoagulant-beta transcript from human placenta, a Ca (2+) dependent phospholipid binding protein that inhibits coagulation and phospholipase A2 activity. However, the fact that annexin VIII is neither an extracellular protein nor associated with the cell surface suggests that it may not play a role in blood coagulation in vivo and its physiological role remains unknown. It is expressed at low levels in human placenta and shows restricted expression in lung endothelia, skin, liver, and kidney. The gene is also found to be selectively overexpressed in acute 203074_at ANXA8 244 602396 annexin A8 myelocytic leukemia.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Supplementary Materials
    Supplementary materials Supplementary Table S1: MGNC compound library Ingredien Molecule Caco- Mol ID MW AlogP OB (%) BBB DL FASA- HL t Name Name 2 shengdi MOL012254 campesterol 400.8 7.63 37.58 1.34 0.98 0.7 0.21 20.2 shengdi MOL000519 coniferin 314.4 3.16 31.11 0.42 -0.2 0.3 0.27 74.6 beta- shengdi MOL000359 414.8 8.08 36.91 1.32 0.99 0.8 0.23 20.2 sitosterol pachymic shengdi MOL000289 528.9 6.54 33.63 0.1 -0.6 0.8 0 9.27 acid Poricoic acid shengdi MOL000291 484.7 5.64 30.52 -0.08 -0.9 0.8 0 8.67 B Chrysanthem shengdi MOL004492 585 8.24 38.72 0.51 -1 0.6 0.3 17.5 axanthin 20- shengdi MOL011455 Hexadecano 418.6 1.91 32.7 -0.24 -0.4 0.7 0.29 104 ylingenol huanglian MOL001454 berberine 336.4 3.45 36.86 1.24 0.57 0.8 0.19 6.57 huanglian MOL013352 Obacunone 454.6 2.68 43.29 0.01 -0.4 0.8 0.31 -13 huanglian MOL002894 berberrubine 322.4 3.2 35.74 1.07 0.17 0.7 0.24 6.46 huanglian MOL002897 epiberberine 336.4 3.45 43.09 1.17 0.4 0.8 0.19 6.1 huanglian MOL002903 (R)-Canadine 339.4 3.4 55.37 1.04 0.57 0.8 0.2 6.41 huanglian MOL002904 Berlambine 351.4 2.49 36.68 0.97 0.17 0.8 0.28 7.33 Corchorosid huanglian MOL002907 404.6 1.34 105 -0.91 -1.3 0.8 0.29 6.68 e A_qt Magnogrand huanglian MOL000622 266.4 1.18 63.71 0.02 -0.2 0.2 0.3 3.17 iolide huanglian MOL000762 Palmidin A 510.5 4.52 35.36 -0.38 -1.5 0.7 0.39 33.2 huanglian MOL000785 palmatine 352.4 3.65 64.6 1.33 0.37 0.7 0.13 2.25 huanglian MOL000098 quercetin 302.3 1.5 46.43 0.05 -0.8 0.3 0.38 14.4 huanglian MOL001458 coptisine 320.3 3.25 30.67 1.21 0.32 0.9 0.26 9.33 huanglian MOL002668 Worenine
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2003/0082511 A1 Brown Et Al
    US 20030082511A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0082511 A1 Brown et al. (43) Pub. Date: May 1, 2003 (54) IDENTIFICATION OF MODULATORY Publication Classification MOLECULES USING INDUCIBLE PROMOTERS (51) Int. Cl." ............................... C12O 1/00; C12O 1/68 (52) U.S. Cl. ..................................................... 435/4; 435/6 (76) Inventors: Steven J. Brown, San Diego, CA (US); Damien J. Dunnington, San Diego, CA (US); Imran Clark, San Diego, CA (57) ABSTRACT (US) Correspondence Address: Methods for identifying an ion channel modulator, a target David B. Waller & Associates membrane receptor modulator molecule, and other modula 5677 Oberlin Drive tory molecules are disclosed, as well as cells and vectors for Suit 214 use in those methods. A polynucleotide encoding target is San Diego, CA 92121 (US) provided in a cell under control of an inducible promoter, and candidate modulatory molecules are contacted with the (21) Appl. No.: 09/965,201 cell after induction of the promoter to ascertain whether a change in a measurable physiological parameter occurs as a (22) Filed: Sep. 25, 2001 result of the candidate modulatory molecule. Patent Application Publication May 1, 2003 Sheet 1 of 8 US 2003/0082511 A1 KCNC1 cDNA F.G. 1 Patent Application Publication May 1, 2003 Sheet 2 of 8 US 2003/0082511 A1 49 - -9 G C EH H EH N t R M h so as se W M M MP N FIG.2 Patent Application Publication May 1, 2003 Sheet 3 of 8 US 2003/0082511 A1 FG. 3 Patent Application Publication May 1, 2003 Sheet 4 of 8 US 2003/0082511 A1 KCNC1 ITREXCHO KC 150 mM KC 2000000 so 100 mM induced Uninduced Steady state O 100 200 300 400 500 600 700 Time (seconds) FIG.
    [Show full text]
  • Figure S1. HAEC ROS Production and ML090 NOX5-Inhibition
    Figure S1. HAEC ROS production and ML090 NOX5-inhibition. (a) Extracellular H2O2 production in HAEC treated with ML090 at different concentrations and 24 h after being infected with GFP and NOX5-β adenoviruses (MOI 100). **p< 0.01, and ****p< 0.0001 vs control NOX5-β-infected cells (ML090, 0 nM). Results expressed as mean ± SEM. Fold increase vs GFP-infected cells with 0 nM of ML090. n= 6. (b) NOX5-β overexpression and DHE oxidation in HAEC. Representative images from three experiments are shown. Intracellular superoxide anion production of HAEC 24 h after infection with GFP and NOX5-β adenoviruses at different MOIs treated or not with ML090 (10 nM). MOI: Multiplicity of infection. Figure S2. Ontology analysis of HAEC infected with NOX5-β. Ontology analysis shows that the response to unfolded protein is the most relevant. Figure S3. UPR mRNA expression in heart of infarcted transgenic mice. n= 12-13. Results expressed as mean ± SEM. Table S1: Altered gene expression due to NOX5-β expression at 12 h (bold, highlighted in yellow). N12hvsG12h N18hvsG18h N24hvsG24h GeneName GeneDescription TranscriptID logFC p-value logFC p-value logFC p-value family with sequence similarity NM_052966 1.45 1.20E-17 2.44 3.27E-19 2.96 6.24E-21 FAM129A 129. member A DnaJ (Hsp40) homolog. NM_001130182 2.19 9.83E-20 2.94 2.90E-19 3.01 1.68E-19 DNAJA4 subfamily A. member 4 phorbol-12-myristate-13-acetate- NM_021127 0.93 1.84E-12 2.41 1.32E-17 2.69 1.43E-18 PMAIP1 induced protein 1 E2F7 E2F transcription factor 7 NM_203394 0.71 8.35E-11 2.20 2.21E-17 2.48 1.84E-18 DnaJ (Hsp40) homolog.
    [Show full text]
  • Ceramide Galactosyltransferase (UGT8) Is a Molecular Marker of Breast Cancer Malignancy and Lung Metastases
    British Journal of Cancer (2010) 103, 524 – 531 & 2010 Cancer Research UK All rights reserved 0007 – 0920/10 www.bjcancer.com Ceramide galactosyltransferase (UGT8) is a molecular marker of breast cancer malignancy and lung metastases 1,6,7 2 3 1 4 1 5 P Dzie¸giel , T Owczarek , E Plaz`uk , A Gomułkiewicz , M Majchrzak , M Podhorska-Około´w , K Driouch , 5 ,2,3 R Lidereau and M Ugorski* 1Department of Histology and Embryology, Medical University, T. Chałubin´skiego 6a, Wrocław 50–368, Poland; 2Department of Biochemistry, Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Environmental and Life Sciences, C. Norwida 31, Wrocław 50–357, Poland; 3 Laboratory of Glycobiology and Cell Interactions, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 4 R. Weigla 12, Wrocław 53–114, Poland; Department of Thoracic Surgery, Medical University, Grabiszyn´ska 105, Wrocław 53–430, Poland; 5 6 ´ Oncogenetics laboratory/INSERM U 735, Saint-Cloud, France; Department of Histology and Embryology, Medical University, Swie¸cickiego 6, 7 Poznan´ 61–781, Poland; Department of Pathology, Lower Silesian Oncology Center, Wrocław 53–413, Pl. Hirszfelda 12, Poland BACKGROUND: It was shown recently on the level of gene expression that UGT8, coding UDP-galactose:ceramide galactosyltransferase, is one of six genes whose elevated expression correlated with a significantly increased the risk of lung metastases in breast cancer patients. In this study primary tumours and their lung metastases as well as breast cancer cell lines were analysed for UGT8 expression at the protein level. METHODS: Expression of UGT8 in breast cancer tissue specimens and breast cancer cell lines was analysed using IHC, real-time PCR and Western blotting.
    [Show full text]
  • Epigenetic Mechanisms Are Involved in the Oncogenic Properties of ZNF518B in Colorectal Cancer
    Epigenetic mechanisms are involved in the oncogenic properties of ZNF518B in colorectal cancer Francisco Gimeno-Valiente, Ángela L. Riffo-Campos, Luis Torres, Noelia Tarazona, Valentina Gambardella, Andrés Cervantes, Gerardo López-Rodas, Luis Franco and Josefa Castillo SUPPLEMENTARY METHODS 1. Selection of genomic sequences for ChIP analysis To select the sequences for ChIP analysis in the five putative target genes, namely, PADI3, ZDHHC2, RGS4, EFNA5 and KAT2B, the genomic region corresponding to the gene was downloaded from Ensembl. Then, zoom was applied to see in detail the promoter, enhancers and regulatory sequences. The details for HCT116 cells were then recovered and the target sequences for factor binding examined. Obviously, there are not data for ZNF518B, but special attention was paid to the target sequences of other zinc-finger containing factors. Finally, the regions that may putatively bind ZNF518B were selected and primers defining amplicons spanning such sequences were searched out. Supplementary Figure S3 gives the location of the amplicons used in each gene. 2. Obtaining the raw data and generating the BAM files for in silico analysis of the effects of EHMT2 and EZH2 silencing The data of siEZH2 (SRR6384524), siG9a (SRR6384526) and siNon-target (SRR6384521) in HCT116 cell line, were downloaded from SRA (Bioproject PRJNA422822, https://www.ncbi. nlm.nih.gov/bioproject/), using SRA-tolkit (https://ncbi.github.io/sra-tools/). All data correspond to RNAseq single end. doBasics = TRUE doAll = FALSE $ fastq-dump -I --split-files SRR6384524 Data quality was checked using the software fastqc (https://www.bioinformatics.babraham. ac.uk /projects/fastqc/). The first low quality removing nucleotides were removed using FASTX- Toolkit (http://hannonlab.cshl.edu/fastxtoolkit/).
    [Show full text]